2FIRSTS New Year Messages 2024: Embrace the Era of Excellence Expelling Mediocrity

Industry Insight by 2FIRSTS
Jan.01.2024
2FIRSTS New Year Messages 2024: Embrace the Era of Excellence Expelling Mediocrity
Embrace the era of excellence expelling mediocrity, an era where the original aspiration of vaping industry is realized to make harm-reduction efforts. This is 2FIRSTS' New Year wish.

Embrace the Era of Excellence Expelling Mediocrity - 2FIRSTS New Year Messages 2024

 

 

This is the first message from 2FIRSTS in 2024. We extend our greetings to operators, researchers, regulators, non-profit organizations, and professionals from the global vaping industry. Happy New Year 2024!

 

In 2023, we have released 7,303 industry articles, conducted over 400 interviews, and hosted 14 live broadcasts of exhibitions on 2firsts.com and 2firsts.cn. We reported on-site from 13 countries and regions, including the U.S., the UK, Russia, the UAE, Indonesia, covering a distance equivalent to circling the Earth 3.2 times.

 

All these efforts serve a simple purpose—to inform you about the significant facts and issues occurring in the global vaping industry.

 

In the past year, a sense of anxiety has spread across the global vaping industry. Small businesses face increased survival pressure, and migrating to niche and emerging markets has become a lifeline. Large enterprises tread on thin ice amid growth stress, regulatory uncertainty, and public scrutiny.

 

Regulatory authorities are also facing mounting pressure. Complicated questions remain to be answered: how to curb the harm of vaping products to minors? How to combat counterfeit goods, and prevent illegal trade? The limitations of enforcement costs create a gap between ideals and reality.

 

Against this backdrop, we believe that the hope for the future can ease our anxiety.

 

Fortunately, global brands are gradually taking shape, possessing recognition and fulfilling social responsibilities to drive compliant development.

 

In traditional, mature e-cigarette markets, such as the EU, the U.S., Russia, and emerging markets, such as Southeast Asia, the Middle East, Africa, South America, regulatory authorities are exploring new policies. Although their opinions differ, the very act of "addressing the issues" is a good start. Non-profit organizations worldwide never cease to speak out and take action, and the power of the public has laid the cornerstone for building confidence.

 

All of this has ignited hope: in the future, positive forces will rise to lead industry development. Global regulatory policies, market environments, and public opinions will provide more opportunities for excellent enterprises and products. Practices that used to earn a competitive advantage by avoiding compliance will lose magic.

 

Embrace the era of excellence expelling mediocrity, an era where the original aspiration of vaping industry is realized to make harm-reduction efforts. This is 2FIRSTS' New Year wish.

 

In 2024, 2FIRSTS will continuously focus on major global industrial events, make presence in various markets, and bring firsthand reports to readers. We will raise more questions and stimulate more discussions. Hopefully, we can connect global industry practitioners with facts, questions, and communication, promoting technology for good and industry for progress.

 

2FIRSTS is willing to join hands with you to open up a brighter future.

 

Happy New Year!

 

2FIRSTS Editorial Department
January 1, 2024

 

Click to jump to the Chinese version
Click to jump to the Spanish version

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | Juul Labs Launches Upgraded JUUL2 Kit in UK With Four Pods at £9.99 and USB-C Charging
Product | Juul Labs Launches Upgraded JUUL2 Kit in UK With Four Pods at £9.99 and USB-C Charging
Juul Labs UK has introduced an upgraded JUUL2 Starter Kit for the UK market in October 2026, retaining a recommended retail price of £9.99 while doubling the number of included pods from two to four. The kit contains Crisp Menthol, Virginia Tobacco, Mango and Watermelon pods. The updated device replaces the previous proprietary charging dock with a USB-C port and offers longer battery life. The kit also features reduced packaging and retains a two-year limited warranty. Distribution is scheduled through major UK retailers, wholesalers, convenience stores and the JUUL UK website.
product
Oct.15
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03
German Customs Seize 115,800 Vapes in €1.4 Million Tax Case
German Customs Seize 115,800 Vapes in €1.4 Million Tax Case
Germany's Magdeburg Main Customs Office seized 115,800 untaxed e-cigarettes containing a combined 4.366 million mL of e-liquid during four truck inspections between August 10 and September 4, 2026. The seizures prevented an estimated €1.397 million in tax losses and set a record for the customs office's jurisdiction. Criminal proceedings have been initiated against four truck drivers. The case follows a separate German investigation involving more than 7.6 million illicit vapes and an estimated €33.3 million in excise-tax losses.
Enforcement
Oct.13
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives